Møller and Hovig *Hereditary Cancer in Clinical Practice* (2018) 16:10
https://doi.org/10.1186/s13053-018-0093-1

Hereditary Cancer in Clinical Practice

RETRACTION NOTE Open Access

Retraction Note to: The *BRCA2* variant c.68–7 T > A is associated with breast cancer

Pål Møller[1,2,3*] and Eivind Hovig[2,4,5]

Retraction

This article [1] has been retracted at the request of the authors. Upon re-review of the data, the authors identified coding errors in this study. Due to an error in the SQL query, the conclusions drawn in the article are incorrect. A re-examination of the data shows that there is no association between familial breast cancer and the BRCA2 variant c.68–7 T > A. Another recent study suggests that the variant is not pathogenic [2]. All authors agree to this retraction.

Author details
[1]Department of Medical Genetics, Research Group Inherited Cancer, Oslo University Hospital, Oslo, Norway. [2]Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway. [3]Center for Hereditary Tumors, HELIOS-Klinikum Wuppertal, University of Witten-Herdecke, Wuppertal, Germany. [4]Institute for Cancer Genetics and Informatics, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway. [5]Department of Informatics, University of Oslo, Oslo, Norway.

Received: 16 April 2018 Accepted: 16 April 2018
Published online: 02 May 2018

References

1. Møller P, et al. The BRCA2 variant c.68-7 T>a is associated with breast cancer. Hered Cancer Clin Pract. 2017;15:20.
2. Colombo M, et al. The BRCA2 c.68-7T > a variant is not pathogenic: a model for clinical calibration of spliceogenicity. Hum Mutat. 2018;39:729–41.

* Correspondence: moller.pal@gmail.com
[1]Department of Medical Genetics, Research Group Inherited Cancer, Oslo University Hospital, Oslo, Norway
[2]Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway
Full list of author information is available at the end of the article